Bortezomib's Effects on Neuroblastoma Cells
Author Information
Author(s): Valérie Combaret, Sandrine Boyault, Iseult Iacono, Stéphanie Brejon, Raphaël Rousseau, Alain Puisieux
Primary Institution: Laboratoire de Recherche Translationnelle, Centre Léon Bérard, Lyon, France
Hypothesis
What are the molecular mechanisms by which bortezomib induces apoptosis in neuroblastoma cells?
Conclusion
Bortezomib can induce apoptosis in neuroblastoma cells, but some cell lines are resistant, and combining it with a p38 MAPK inhibitor may enhance its effectiveness.
Supporting Evidence
- Bortezomib showed dose-dependent cytotoxic activity in neuroblastoma cell lines.
- Sensitive cell lines had a higher percentage of apoptotic cells compared to resistant ones.
- Combining bortezomib with a p38 MAPK inhibitor increased cytotoxicity in resistant cell lines.
Takeaway
Bortezomib is a drug that can kill cancer cells, but some cancer cells are tough and don't die. Using another drug can help make bortezomib work better.
Methodology
The study involved testing the effects of bortezomib on 12 neuroblastoma cell lines using various assays to measure cell viability and apoptosis.
Limitations
The study focused on a limited number of neuroblastoma cell lines and did not explore all potential molecular mechanisms of resistance.
Participant Demographics
The study involved various neuroblastoma cell lines, but specific demographic details of the original patient samples are not provided.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website